PABAF (Patrys) Moat Score: 2/10 (As of Jun. 28, 2026)


What is Patrys Moat Score?

Patrys PABAF Moat Score is 2 as of Jun. 28, 2026. The stock has 1 warning sign investors should review. Among 1,402 Biotechnology companies, Patrys ranks better than 58.06% on this metric.

Patrys has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Patrys has No Moat: Patrys Ltd lacks significant market leadership or proprietary technology. The company does not exhibit strong brand strength or customer loyalty, and there are no substantial regulatory barriers or exclusive licenses. Its competitive advantages are weak and transient, with no clear evidence of durable cost advantages or network effects.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Patrys might have No Moat - Very weak/transient advantages.

Patrys  (OTCPK:PABAF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Patrys Moat Score Related Terms

PABAF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Patrys's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Patrys Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Patrys's Moat Score distribution charts can be found below:

* The bar in red indicates where Patrys's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Patrys (PABAF) has a Moat Score of 2 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Patrys ranks #588 out of 1402 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Patrys' Moat Score too high?
Patrys' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Patrys' value of 2 is 0% at this industry median. Based on the distribution chart, Patrys ranks #588 out of 1402 companies in the Biotechnology industry, which is above the industry midpoint.
How does Patrys' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Patrys ranks #588 out of 1402 companies for Moat Score. This puts Patrys in the upper half of its industry. The industry median Moat Score is 2.00. Patrys' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Patrys's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Patrys's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Patrys stock overvalued right now?
Patrys (PABAF) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Patrys (PABAF), the current Moat Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Patrys Business Description

Other Exchanges PABDA:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Patrys Ltd is a biopharmaceutical company focused on developing novel antibody-based therapies prominently for cancer and related inflammatory diseases. Its core technology platform involves antibodies that penetrate cell nuclei and inhibit cancer cell DNA repair mechanisms. The company advances therapeutic candidates from its antibody platforms, including ones licensed from Yale University, with ongoing preclinical and clinical development activities. Patrys generates revenue through licensing agreements and collaborations linked to its antibody technologies. Its operations and development efforts span Australia and the United States.